Related Experiment Video

Updated: Aug 8, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Mammalian target of rapamycin inhibitors in sarcomas

Scott Okuno1

  • 1Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. okuno.scott@mayo.edu

Current Opinion in Oncology
|May 25, 2006
PubMed
Abstract

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise for treating advanced sarcomas, offering improved outcomes beyond standard chemotherapy. Recent studies demonstrate clinical benefit response in sarcoma patients treated with these novel agents.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sarcomas represent a rare but aggressive group of cancers with limited treatment options.
  • Standard chemotherapy offers a low response rate for advanced sarcomas, necessitating novel therapeutic strategies.
  • The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and survival, making it a potential therapeutic target.

Purpose of the Study:

  • To review the emerging role of mammalian target of rapamycin (mTOR) inhibitors in sarcoma treatment.
  • To evaluate the efficacy and potential of mTOR inhibitors as novel agents against advanced sarcomas.
  • To discuss the clinical benefit response endpoint in assessing new sarcoma therapies.

Main Methods:

  • Review of recent clinical studies and research on mTOR inhibitors in sarcoma.
  • Analysis of data evaluating clinical benefit response, including complete response, partial response, and stable disease.
  • Examination of specific mTOR inhibitors like AP23573 and RAD001 (everolimus) in sarcoma treatment.

Main Results:

  • Recent studies indicate that mammalian target of rapamycin (mTOR) inhibitors demonstrate clinical benefit response in sarcomas.
  • The mTOR inhibitor AP23573 has shown activity against sarcomas.
  • RAD001 (everolimus) combined with imatinib shows promise in imatinib-resistant gastrointestinal stromal tumors.

Conclusions:

  • The clinical benefit response endpoint effectively identifies promising new agents for sarcoma treatment.
  • mTOR inhibitors represent a promising class of drugs for advanced sarcomas.
  • Further research is needed to differentiate the clinical efficacy of various mTOR inhibitors across sarcoma subtypes.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...